Sareum (LON:SAR) Shares Up 12.2% – Still a Buy?

Shares of Sareum Holdings plc (LON:SAR) shot up 12.2% during mid-day trading on Thursday . The stock traded as high as GBX 23.89 and last traded at GBX 23. 310,180 shares traded hands during trading, an increase of 40% from the average session volume of 221,107 shares. The stock had previously closed at GBX 20.50.

Sareum Trading Up 4.8%

The firm has a market capitalization of £34.71 million, a price-to-earnings ratio of -6.45 and a beta of -1.08. The company has a 50-day moving average of GBX 19.04 and a 200-day moving average of GBX 16.99.

Sareum (LON:SAR) last issued its quarterly earnings data on Thursday, March 12th. The company reported GBX (1.20) EPS for the quarter. On average, research analysts forecast that Sareum Holdings plc will post -3.8 earnings per share for the current year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.